Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rubicon ResearchNSE:RUBICON +1.45%18 PB Ratio is 18.40 as of Jul. 20, 2026, which is 7% above its 10-year median of 17.15. GuruFocus rates NSE:RUBICON with a GF Score™ of 18/100. The stock has 3 warning signs investors should review. Among 924 Drug Manufacturers companies, Rubicon Research ranks worse than 96.65% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-20), Rubicon Research's share price is ₹1439.60. Rubicon Research's Book Value per Share for the quarter that ended in Mar. 2026 was ₹78.23. Hence, Rubicon Research's PB Ratio of today is 18.40.
Warning Sign:
Rubicon Research Ltd stock PB Ratio (=18.4) is close to 1-year high of 19.81.
The historical rank and industry rank for Rubicon Research's PB Ratio or its related term are showing as below:
NSE:RUBICON'
s PB Ratio Range Over the Past 10 Years
Min: 9.9 Med: 17.15 Max: 19.81
Current: 18.4
During the past 4 years, Rubicon Research's highest PB Ratio was 19.81. The lowest was 9.90. And the median was 17.15.
NSE:RUBICON's PB Ratio is ranked worse than 96.65% of 924
companies
in the Drug Manufacturers industry
Industry Median: 1.895
vs NSE:RUBICON: 18.40
During the past 12 months, Rubicon Research's average Book Value Per Share Growth Rate was 138.20% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 65.10% per year.
During the past 4 years, the highest 3-Year average Book Value Per Share Growth Rate of Rubicon Research was 65.10% per year. The lowest was 65.10% per year. And the median was 65.10% per year.
Back to Basics: PB Ratio
Rubicon Research (NSE:RUBICON) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Rubicon Research PB Ratio Related Terms
Rubicon Research PB Ratio Historical Data
* Premium members only.
The historical data trend for Rubicon Research's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:RUBICON vs LLY, JNJ, ABBV: PB Ratio Comparison
For the Drug Manufacturers - General subindustry, Rubicon Research's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rubicon Research PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Rubicon Research's PB Ratio distribution charts can be found below:
* The bar in red indicates where Rubicon Research's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Rubicon Research (NSE:RUBICON) has a PB Ratio of 18.40 as of Jul. 20, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Rubicon Research and its competitors. This is near median its historical median of 17.15. Over the past decade, Rubicon Research's PB Ratio has ranged from 9.90 to 19.81. According to the industry distribution chart, Rubicon Research ranks #893 out of 924 companies in the Drug Manufacturers industry, placing it in the top 96.6%.
Is Rubicon Research's PB Ratio too high?
Rubicon Research's current PB Ratio of 18.40 is near median its 10-year median of 17.15. Over the past 10 years, this metric has ranged from a low of 9.90 to a high of 19.81. The Drug Manufacturers industry median PB Ratio is 1.90. Rubicon Research's value of 18.40 is 871% above this industry median. Based on the distribution chart, Rubicon Research ranks #893 out of 924 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Rubicon Research has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Rubicon Research's PB Ratio compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Rubicon Research ranks #893 out of 924 companies for PB Ratio. This places Rubicon Research in the lower half of its industry. The industry median PB Ratio is 1.90. Rubicon Research's value of 18.40 is 871% above this benchmark. Historically, Rubicon Research's own PB Ratio has ranged from 9.90 to 19.81 over the past decade. While the company's 10-year median is 17.15 vs. the industry median of 1.90, Rubicon Research has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.90, based on 924 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rubicon Research's current PB Ratio of 18.40 is 871% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Rubicon Research and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rubicon Research's current PB Ratio is 18.40, which is near median its own 10-year median of 17.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rubicon Research stock overvalued right now?
Rubicon Research (NSE:RUBICON) has a current PB Ratio of 18.40. The current PB Ratio is 18.40, which is near median its 10-year median of 17.15 and 871% above the Drug Manufacturers industry median of 1.90. Rubicon Research's overall GF Score™ is 18/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Rubicon Research (NSE:RUBICON), the current PB Ratio is 18.40 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Rubicon Research Ltd is a pharmaceutical formulations company specializing in developing, manufacturing, and marketing branded specialty and generic prescription products. Starting as a provider of contract formulation development services, the company expanded to operate an oral solids manufacturing facility in India, offering contract development and manufacturing services for regulated markets. The company's diverse product portfolio covers multiple therapeutic areas, including analgesics and pain management, CVS, CNS, hypokalemia, skeletal muscle relaxants, NRT, gastrointestinal, metabolic, and immunosuppressants. The company operates in India, the USA, and other markets, with the majority of its revenue coming from the USA.
18GF Score
Get the complete analysis for NSE:RUBICON
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:RUBICON has been successfully added to your 
